Results 101 to 110 of about 14,468 (231)

Remission in Global Airway Diseases: EUFOREA Consensus Paper

open access: yesAllergy, EarlyView.
ABSTRACT The therapeutic goal in chronic airway diseases is shifting from symptom control to disease remission. Disease‐modifying therapies, including biologics and allergen immunotherapy, have made remission achievable in patients with severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), or allergic rhinitis (AR).
J. Christian Virchow   +22 more
wiley   +1 more source

Complications due to acute rhinosinusitis in children

open access: yes, 2021
Background: There is a lack of population-based studies of complications to acute rhinosinusitis in children. Previous studies have demonstrated a possible effect of the conjugate pneumococcal vaccine (PCV) on hospital admissions and bacteriology in ...
Sofia Hultman Dennison (18649105)
core  

Management of acute rhinosinusitis in children

open access: yesPaediatric Respiratory Reviews
Acute rhinosinusitis (ARS) is a common condition in children, usually preceded by a viral upper respiratory tract infection (URTI). Diagnosing ARS can be challenging, relying primarily on clinical history and examination. Differentiating between viral URTI, post-viral ARS and acute bacterial rhinosinusitis (ABRS) is crucial for guiding appropriate ...
Yanisa, Wannasuphoprasit   +1 more
openaire   +2 more sources

Melioidosis in companion animals: Analysis of 45 Australian cases (24 dogs; 21 cats) from 1997 to 2025 and a brief review of the animal and human literature

open access: yesAustralian Veterinary Journal, EarlyView.
Objective To report 45 cases of melioidosis in dogs and cats from northern Australia and analyse trends in epidemiology, clinical presentation, pathogenesis and response to treatment over a 27‐year period. Design Retrospective and prospective analysis of clinical records.
K Lee   +6 more
wiley   +1 more source

Thrombophlebitis of the temporal vein as an extracranial complication of acute bacterial rhinosinusitis

open access: yes, 2015
A 39-year-old white man presented with a swollen left upper eyelid secondary to progressive acute bacterial rhinosinusitis (ABRS). Physical examination found a 40% reduction in vision in the left eye and right-sided erythematous temporal swelling with ...
Caversaccio, Marco, Huth, Markus
core  

Could seasonal allergy be a risk factor for acute rhinosinusitis in children?

open access: yes, 2018
Objective:: To evaluate the incidence of acute rhinosinusitis in children with grass pollen induced rhinitis during the period of grass pollinosis. Methods:: Children with nasal symptoms from grass pollen induced rhinitis but without rhinosinusitis ...
A Cazzavillan   +9 more
core   +1 more source

Medical and social aspects of acute rhinosinusitis treatment

open access: yes, 2018
Проблема гострих запальних захворювань верхніх дихальних шляхів, гострого риносинуситу зокрема, є однією з актуальних проблем сучасної оториноларингології.
Макаренко, О. В.   +3 more
core   +1 more source

Clinical Evidence and Biomarkers Linking Allergy and Acute or Chronic Rhinosinusitis in Children: a Systematic Review

open access: yes, 2020
Purpose of the Review: We provide a systematic review of experimental and clinical evidences linking allergy to acute, including common cold, and chronic rhinosinusitis in children.
Lucidi D   +18 more
core   +1 more source

Asthma and Multimorbidity Amongst Ethnic Minority Groups in High Income Countries

open access: yesClinical &Experimental Allergy, EarlyView.
There is a tight intersection between asthma, deprivation, ethnicity, multimorbidity and poor clinical outcomes. An integrated, holistic and culturally tailored approach is needed to improve clinical outcomes amongst ethnic minority groups with asthma and multimorbidity. ABSTRACT Asthma is one of the commonest noncommunicable diseases worldwide.
Mamidipudi Thirumala Krishna   +6 more
wiley   +1 more source

Emerging Paediatric Uses of Dupilumab Beyond Approvals

open access: yesClinical &Experimental Allergy, EarlyView.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy